Literature DB >> 8392075

Hexadecylphosphocholine differs from conventional cytostatic agents.

M R Berger1, B Betsch, M Gebelein, E Amtmann, P Heyl, H R Scherf.   

Abstract

Alkylphosphocholines, and especially their main representative hexadecylphosphocholine (HPC), show high anticancer activity in methylnitrosourea (MNU)-induced autochthonous rat mammary carcinoma. The regression of MNU-induced rat mammary carcinoma during HPC treatment can be evaluated by computed tomography and sonography. This allows a noninvasive monitoring of therapy in vivo (tumor size, morphology, and blood supply). Both diagnostic modalities can show a rapid concentric decrease in tumor volume as well as the appearance of cystic, scarry, and necrotic areas in the tumor tissue as a result of HPC treatment. In addition, prior to, during and after therapy tumor perfusion can be assessed by color Doppler sonography in vivo. A more than 4-fold difference in HPC efficacy was observed when the colony growth of explanted MNU-induced mammary carcinoma cells was measured in the methylcellulose colony assay (IC50 = 180 mumol HPC/l) and the Hamburger Salmon colony assay (IC50 = 740 mumol HPC/l). In the latter assay, growth of concomitantly seeded untransformed cells, especially of fibroblasts, is much lower than in the methyl-cellulose colony assay. We therefore assume that the antitumor efficacy of HPC against MNU-induced mammary carcinoma is enhanced by neighboring cells such as fibroblasts. Cell culture experiments with the three MNU-induced rat mammary carcinoma cell clones 1-C-2, 1-C-30, and 1-C-32 revealed IC50 values in the range of 50-70 mumol HPC/l. The volume of 1-C-2 cells increased up to 4-fold after 72 h of permanent exposure to 100 mumol HPC/l, a concentration that completely inhibited proliferation of tumor cell numbers without being cytotoxic. Nucleotide triphosphate levels dropped significantly after 24 h and were slowly restored in spite of continued exposure. After 72 h, they nearly reached those levels observed in plateau-phase cells. This suggests that HPC-induced growth inhibition has similarities with physiologically occurring growth arrest. Finally, replication of RNA viruses and DNA viruses was suppressed 30-fold and 7-fold, respectively, at low concentrations of HPC (12 mumol/l), which caused no or negligible growth inhibition in the virus-harboring cells, thus demonstrating specific antiviral activity of HPC. From these observations we conclude that HPC differs in many important aspects from conventional cytostatic agents and is certainly worth following-up in further investigations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392075     DOI: 10.1007/bf01686464

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas.

Authors:  M R Berger; P Yanapirut; M Reinhardt; T Klenner; H R Scherf; H H Schmeiser; H Eibl
Journal:  Prog Exp Tumor Res       Date:  1992

Review 2.  Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening.

Authors:  H R Maurer; P Hilgard
Journal:  Prog Exp Tumor Res       Date:  1992

3.  Inhibition of c-fos transcription and phosphorylation of the serum response factor by an inhibitor of phospholipase C-type reactions.

Authors:  G Schalasta; C Doppler
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

4.  Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells.

Authors:  M Shoji; R L Raynor; E A Fleer; H Eibl; W R Vogler; J F Kuo
Journal:  Lipids       Date:  1991-02       Impact factor: 1.880

5.  Significance of freshly cultured fibroblasts from different tissues in promoting cancer cell growth.

Authors:  H Mukaida; N Hirabayashi; T Hirai; T Iwata; S Saeki; T Toge
Journal:  Int J Cancer       Date:  1991-05-30       Impact factor: 7.396

6.  Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.

Authors:  C Unger; M Peukert; H Sindermann; P Hilgard; G Nagel; H Eibl
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

7.  Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.

Authors:  J Kötting; M R Berger; C Unger; H Eibl
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Alkyl phosphocholines: toxicity and anticancer properties.

Authors:  C Muschiol; M R Berger; B Schuler; H R Scherf; F T Garzon; W J Zeller; C Unger; H J Eibl; D Schmähl
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

9.  Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo.

Authors:  S B Sobottka; M R Berger; H Eibl
Journal:  Int J Cancer       Date:  1993-02-01       Impact factor: 7.396

10.  Stromal influences on breast cancer cell growth.

Authors:  C E van Roozendaal; B van Ooijen; J G Klijn; C Claassen; A M Eggermont; S C Henzen-Logmans; J A Foekens
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more
  2 in total

1.  Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins.

Authors:  Ilina K Dineva; Maya M Zaharieva; Spiro M Konstantinov; Hansjörg Eibl; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-30       Impact factor: 4.553

Review 2.  Multiple Facets of Autophagy and the Emerging Role of Alkylphosphocholines as Autophagy Modulators.

Authors:  Ferda Kaleağasıoğlu; Doaa M Ali; Martin R Berger
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.